Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2920369rdf:typepubmed:Citationlld:pubmed
pubmed-article:2920369lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:2920369lifeskim:mentionsumls-concept:C0151779lld:lifeskim
pubmed-article:2920369lifeskim:mentionsumls-concept:C0441767lld:lifeskim
pubmed-article:2920369lifeskim:mentionsumls-concept:C1514474lld:lifeskim
pubmed-article:2920369lifeskim:mentionsumls-concept:C0175860lld:lifeskim
pubmed-article:2920369lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:2920369pubmed:issue7lld:pubmed
pubmed-article:2920369pubmed:dateCreated1989-4-18lld:pubmed
pubmed-article:2920369pubmed:abstractTextThe survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage II) were studied. Eighty-seven of 377 Stage I patients (23%) developed regional nodal metastases (Stage IIB) with 40% 5-year survival. Fifty patients had regional nodal metastases at presentation, with or without a known primary (Stages IIA or IIC, respectively), with a 42% 5-year survival. A step-down multivariate analysis using the Cox regression model revealed four risk factors as being highly significant for predicting a more favorable survival outcome: (1) thinner Breslow thickness (P = 0.0001), (2) pathologic Stage I disease (P = 0.004), (3) no clinical ulceration (P = 0.0004), and (4) being a woman younger than 50 years of age (P = 0.029). These results are discussed in reference to other series.lld:pubmed
pubmed-article:2920369pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2920369pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2920369pubmed:languageenglld:pubmed
pubmed-article:2920369pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2920369pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2920369pubmed:statusMEDLINElld:pubmed
pubmed-article:2920369pubmed:monthAprlld:pubmed
pubmed-article:2920369pubmed:issn0008-543Xlld:pubmed
pubmed-article:2920369pubmed:authorpubmed-author:MoonT ETElld:pubmed
pubmed-article:2920369pubmed:authorpubmed-author:MeyskensF...lld:pubmed
pubmed-article:2920369pubmed:authorpubmed-author:TomsAAlld:pubmed
pubmed-article:2920369pubmed:authorpubmed-author:ParksBBlld:pubmed
pubmed-article:2920369pubmed:authorpubmed-author:BerdeauxD HDHlld:pubmed
pubmed-article:2920369pubmed:authorpubmed-author:LoescherLLlld:pubmed
pubmed-article:2920369pubmed:issnTypePrintlld:pubmed
pubmed-article:2920369pubmed:day1lld:pubmed
pubmed-article:2920369pubmed:volume63lld:pubmed
pubmed-article:2920369pubmed:ownerNLMlld:pubmed
pubmed-article:2920369pubmed:authorsCompleteYlld:pubmed
pubmed-article:2920369pubmed:pagination1430-6lld:pubmed
pubmed-article:2920369pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:meshHeadingpubmed-meshheading:2920369-...lld:pubmed
pubmed-article:2920369pubmed:year1989lld:pubmed
pubmed-article:2920369pubmed:articleTitleCutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease.lld:pubmed
pubmed-article:2920369pubmed:affiliationDepartment of Internal Medicine, Arizona Cancer Center, Tucson.lld:pubmed
pubmed-article:2920369pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2920369pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2920369lld:pubmed